Department Of Urology Articles

Articles

GU Cancers Symposium 2012 - Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA) - Session Highlights
SAN FRANCISCO, CA, USA (UroToday.com) - Results from ALSYMPCA trial reveal that radium-223 chloride, a local-acting calcium mimetic, significantly prolongs both overall survival and the time to the first skeletal-related event (SRE), compared with placebo, in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
Published February 8, 2012
Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide - Abstract

Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory.

Published January 25, 2012